Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
CHAPTER 40

COVID-19 Infection: A Novel Fatal Pandemic of the World in 2020

MAJID MALEKIa • ZEINAB NOROUZIb • ALIREZA MALEKIC
aRajaie Cardiovascular, Medical & Research Center, Iran University of Medical Sciences, Tehran, Iran,
bCardiac Rehabilitation Department, Rajaie Cardiovascular, Medical & Research Center, Tehran, Iran,
cResident of Anesthesiology, Iran University of Medical Sciences, Tehran, Iran

EPIDEMIOLOGY

A respiratory syndrome with a novel coronavirus called COVID-19 was diagnosed on November 17, 2019 for the first time in Wuhan, China1 and it was reported to WHO (World Health Organization) on December 31, 2019.2 In a short time, the infection with this virus spread and was reported from other countries; and in less than a few months a pandemic has happened and many countries were involved with the COVID-19 virus. Corona infection outbreak was reported from more than 210 countries3 and most cases were reported from Europe and America although every part of the globe was involved too. According to the last updated report of WHO, the highest prevalence of the infection has occurred in several countries including the United States, India, Brazil, France, Russian Federation, Spain, United Kingdom, Argentina, Italy, and Colombia.4

According to the genetic data, it seems that the COVID-19 virus is related to two other viruses including Middle East Respiratory Syndrome coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome coronavirus (SARS-CoV).5 The symptoms of these two viruses are more severe, but COVID-19 can spread faster and infect more patients in comparison with MERS-CoV and SARS-CoV.6

SIGNS AND SYMPTOMS

The virus can infect the cells by using the receptors of the angiotensin-converting enzyme (ACE) that is connected with the renin–angiotensin–aldosterone system (RAAS).7 The incubation period has a wide range, from 0 to 24 days and the average time is 3 days.8

COVID-19 infection may present large spectrum of signs and symptoms. On the one hand, it can occur as an asymptomatic infection, and on the other hand, severe life-threatening pneumonia may happen.9

Pneumonia is one of the first ominous findings in corona infection.10 Fever and cough are the most common symptoms. Other common clinical manifestation includes fatigue, myalgia, and dyspnea. Some patients may experience pharyngalgia, headache, diarrhea, rhinorrhea, and sore throat.11 Pneumonia can gradually become worse and the patient may suffer severe respiratory distress8 and in the cases with severe hypoxia mechanical ventilator may be necessary although it is recommended not to use ventilator support as far as possible. Some studies showed that coronavirus infection can deteriorate faster in elderly patients and the time between the beginning of the disease until death is shorter in comparison with young patients.12 Young patients may experience gastrointestinal symptoms or may even be completely asymptomatic10 (Figs. 40.1 and 40.2).

In the first months of the pandemic, a Chest CT (computerized tomography) scan was used for screening COVID-19 infection in the suspected patients.13,14 The findings of the CT scan include ground-glass opacity (GGO), consolidation, and interlobular septal thickening. In many CT scans, multiple lesions are seen.15 With improvement in the experience of COVID-19 some data suggested that RT-PCR (reverse transcription polymerase chain reaction) is superior in comparison with chest CT scan.16 However, several studies reported false-negative results from RT-PCR.17 Although technology is improving, clinical judgment plays an important role in controlling the pandemic. Health-care providers should not rely on imaging or laboratory tests alone. Early diagnosis even with negative paraclinical data and quarantining the patients soon can effectively prevent the spreading of the disease16 (Figs. 40.3 and 40.4).
TREATMENT

The definite treatment for COVID-19 infection is not clear yet. In some studies, empirical therapy, Oseltamivir, Ganciclovir, and Lopinavir/ritonavir were used. Several studies suggest interleukin-6 antibody blockers (e.g., Tocilizumab in severe disease), convalescent plasma transfusion, and stem cell therapy to control the cytokine storm of the infection. Other studies suggested nucleoside analogs, HIV-protease inhibitors, and remdesivir. Several other drugs are under study and more clinical trials should be done for introducing an effective drug and also a vaccination for this pandemic life-threatening infection.

COVID-19 AND CARDIOVASCULAR DISEASE

According to some unpublished research, COVID-19 may damage the heart in up to 20% of the patients. It is still unclear if the virus attacks the heart directly. Although concentration in the COVID-19 pandemic is on the respiratory system with providing good ventilation, many physicians in the front line are talking about its effects on the cardiovascular system and death due to cardiac arrest. There is much data from China, Italy, and other countries that show this disease can infect heart muscle with subsequent heart failure and death.

The risk of mortality and morbidity is higher in patients with underlying cardiovascular disease. It is unclear if the virus or body response to virus injury may introduce cardiovascular disorders although it is difficult to conclude that the virus by itself can affect a healthy heart. It is almost clear that preexisting heart problems can aggravate the disease with the acceleration of congestive heart failure. In addition, the infection causes some difficulties in heart transplants and the management of the patients after surgery.
As mentioned in the previous sections, the infection can occur by using ACE receptors by the virus. In addition, this receptor plays an important role in cardiovascular diseases, hypertension, and diabetes mellitus. Inhibition of the RAAS by using ACE inhibitors or angiotensin-receptor blockers (ARB) can upregulate the ACE receptors and lead to severe infection. Several studies revealed that the risk of infection with COVID-19 and also the severity of the disease is higher in the patients with hypertension, diabetes mellitus, coronary heart disease, and cerebrovascular disease who were under treatment with ACE inhibitors before the infection. The corona virus attaches itself to some receptors in the lungs; the same happens in heart muscle as well. According to some data that must be proved, if a patient is using these drugs, it is advisable to choose other antihypertensive drugs such as calcium channel blockers (CCB).

In addition to ACE receptors, cytokine storm, respiratory distress and hypoxia in COVID-19 infection can cause myocardial damage. In addition, the patients should be monitored for probable cardiovascular complications due to antiviral or antimicrobial drugs such as hydroxychloroquine which may cause malignant arrhythmia due to long QT arrhythmia; and also, they should be followed up for latent cardiovascular disease. It must be pointed out that after hopeful termination of such a pandemic situation many patients may suffer heart problems as one of the worst late complications due to COVID-19 and cardiologists must prepare themselves for diagnosis, treatment, and follow up of these patients.

It is known that since many years ago and according to several studies, a condition like pneumonia and any kind of widespread inflammation in the body may damage the heart and even lead to plaques in the arteries or making them unstable with subsequent heart attacks. Furthermore, myocarditis and cardiomyopathies are among the results of these kinds of inflammations and perhaps COVID-19.

New protocols should be implemented in the patients with suspected COVID-19, especially in heart attacks, which may mimic acute ST-elevation or non-ST-elevation myocardial infarction to avoid an unnecessary rush to catheterization laboratory or providing facilities for primary PCI (percutaneous coronary intervention).

Interestingly, some reports show that the mortality rate from heart damage due to myocarditis in patients with a previous healthy heart is more than in patients with preexisting heart damage. It is also worth noting that the patients with preexisting heart problems had less mortality than the ones with normal cardiovascular disorders who developed myocarditis due to COVID-19. It will be valuable if a risk score can be developed for clinicians to help them better observe the patients, who may develop heart failure during the disease.

Some clinicians recommend daily electrocardiography, echocardiography, and measurement of biomarkers to identify patients at risk of developing cardiovascular disease due to corona infection as a part of a routine management of the disease. Although according to some data evaluating these patients may increase additional staff into the room and more exposure, especially in the era of limited masks or protective equipment.

FIG. 40.3 The CT scan of a 31-year-old male showed a ground-glass opacity in the upper lobe of the right lung. He was treated with the diagnosis of COVID-19 infection.

FIG. 40.4 A 76-year-old female with fever, dyspnea, and cough was admitted to the hospital. In the CT scan, bilateral subpleural ground-glass opacity with central extension was seen. She was treated with the diagnosis of COVID-19 infection.
It is emphasized that the physician must pay a lot of attention to the patients with COVID-19 infection who had a history of cardiovascular disease. This special group of the patients is at a higher risk of cardiac complications including cardiovascular events.34

Managing the patients with STEMI (ST-elevation myocardial infarction) is an issue. On the one hand, several studies suggested thrombolytic therapy during the corona pandemic35–37 for preventing transmission of the virus. On the other hand, primary PCI is recommended for the patients with definite criteria for COVID-19 and STEMI. A study in a tertiary center for cardiovascular disease by Firouzi et al. showed that although corona infection is common due to the recent pandemic, primary PCI is still the gold standard for managing the patients with STEMI even in those who have definite criteria for COVID-19. Personal protective equipment is essential and is the first step to approach to these patients.38 In addition, several studies showed that during the COVID-19 pandemic, the delay for the patients’ referral and treatment was increased significantly.39,40

Asymptomatic carriers are one of the serious sources of the infection and can play an important role in spreading the infection for many people silently,41 and evaluating the patients and health-care providers before any interventional procedures is essential.

In conclusion, there is not any specific treatment or vaccination for COVID-19 infection; so, prevention plays an important role in controlling the burden of the disease. Simple actions like isolating the patients, using suitable masks, better personal hygiene, and good ventilation can prevent the infection.42

It is emphasized that the health-care provider’s role for controlling this pandemic is early diagnosis of the patients with COVID-19 infection. Getting a complete history of the symptoms and underlying diseases, careful physical examination with full protection for themselves and history of the recent exposure with other patients with corona infection plays an important role in early diagnosis. The suspected patients must be quarantined as soon as possible and the physicians should not postpone their management until doing the paraclinical evaluations. In addition, educating all the members of the society for self-care is essential in preventing this serious infection.

ACKNOWLEDGMENT
We want to especially thank Dr. Zahra Aires, the resident of Radiology from Boali Hospital, Zahedan University of Medical Sciences (ZAUMS) in Iran, for her time and attention for preparing the photos of this chapter and the CT scans of the patients with the diagnosis of COVID-19 infection.

REFERENCES
1. https://www.theguardian.com/world/2020/mar/13/first-covid-19-case-happened-in-november-china-government-records-show-report.
2. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen.
3. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
4. https://covid19.who.int/.
5. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. Nature. 2020; https://doi.org/10.1038/s41586-020-2012-7.
6. Kannan S, Ali PSS, Sheeza A, Hemalatha K. COVID-19 (novel coronavirus 2019)—recent trends. Eur Rev Med Pharmacol Sci. 2020; 24:2006–2011.
7. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020; https://doi.org/10.1056/NEJMr2005760.
8. Guan W, Ni Z, Yu H, et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv. 2020; 382:1708–1720. Preprint posted online on Feb. 9 https://doi.org/10.1101/2020.02.06.20020974.
9. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382:727–733. https://doi.org/10.1056/NEJMoa2001017 [Epub ahead of print].
10. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395:P514–P523. https://doi.org/10.1016/S0140-6736(20)30154-9.
11. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395:507–513. https://doi.org/10.1016/S0140-6736(20)30211-7.
12. Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. 2020; 92:1–4. https://doi.org/10.1002/jmv.257224.
13. Fang Y, Zhang H, Xie J, et al. The sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology. 2020; 19: E115–E117.
14. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020; 200642.
15. Wu J, Wu X, Zeng W, et al. Chest CT findings in patients with corona virus disease 2019 and its relationship with
clinical features. *Invest Radiol.* 2020; 55:257–261. https://doi.org/10.1097/RLI.0000000000000670.

16. Yang W, Yan F. Patients with RT-PCR-confirmed COVID-19 and normal chest CT. *Radiology.* 2020; 295. https://doi.org/10.1148/radiol.2020200702.

17. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. *Radiology.* 2020; 20200343. https://doi.org/10.1148/radiol.20200343PubMedGoogleScholar Published online February 12.

18. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020; 395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.

19. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA.* 2020; 323:1061–1069. https://doi.org/10.1001/jama.2020.1585 [Epub ahead of print].

20. Chen C, Zhang X, Ji Z, He W. Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies. *Zhonghua Shao Shang Za Zhi.* 2020; 36:E005. https://doi.org/10.3760/cma.j.cn501120-20200224-00088 Epub ahead of print.

21. Xu X, Han M, Li T, et al. n.d. Effective Treatment of Severe COVID-19 Patients With Tocilizumab, *Proc Natl Acad Sci U S A.* 2020 May 19;117(20):10970–10975. Published online 2020 Apr 29. https://doi.org/10.1073/pnas.2005615117.

22. Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in humans: a descriptive study. *Chin Med J.* 2020; 133:1015–1024. https://doi.org/10.1097/CME9.000000000000722.

23. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res.* 2020; 30: 269–271.

24. Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. *Circulation.* 2020; 141:1648–1655. https://doi.org/10.1161/CIRCULATIONAHA.120.046941.

25. Chen C, Yan JT, Zhou N, Zhao JP, Wang DW. Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19. *Zhonghua Xin Xue Guan Bing Za Zhi.* 2020; 48:E008. https://doi.org/10.3760/cma.j.cn112148-20200225-00123.

26. Turner AI, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. *Trends Pharmacol Sci.* 2004; 25:291–294.

27. Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. *Nat Rev Cardiol.* 2020.

28. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med.* 2020; 8: P475–P481. published online Feb 24https://doi.org/10.1016/S2223-2600(20)30079-5.

29. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med.* 2020; 382:18. https://doi.org/10.1056/NEJMoal2002032 published online Feb 28.

30. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China. *Allergy.* 2020; 75:1730–1741. https://doi.org/10.1111/all.14238 published online Feb 19.

31. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *Lancet Respir Med.* 2020; 8(4):PE21. https://doi.org/10.1016/S2223-2600(20)30116-8.

32. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020; 395:497–506.

33. Wong CK, Lam CWK, Wu AKL, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. *Clin Exp Immunol.* 2004; 136:95–103.

34. Alemzadeh-Ansari MJ. Coronavirus disease 2019 (COVID-19) and cardiovascular events. *Res Cardiovasc Med.* 2020; 9:1–2.

35. Zeng J, Huang J, Pan L. How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan provincial People’s hospital. *Intensive Care Med.* 2020; 46:1111–1113.

36. Welt FGP, Shah PB, Aronow HD, et al. Catheterization laboratory considerations during the coronavirus (COVID-19) pandemic: from ACC’s Interventional Council and ESCAI. *J Am Coll Cardiol.* 2020; 75:2372–2375.

37. Sadeghipour P, Talasaz AH, Eslami V, et al. Management of ST-segment-elevation myocardial infarction during the coronavirus disease 2019 (COVID-19) outbreak: Iranian “247” National Committee’s position paper on primary percutaneous coronary intervention. *Catheter Cardiovasc Interv.* 2020; .

38. Firouzi A, et al. Effects of the COVID-19 pandemic on the management of patients with ST-elevation myocardial infarction in a Tertiary Cardiovascular Center. *Crit Pathw Cardiol.* 2020; https://doi.org/10.1097/HPC.000000000000228 Volume Publish Ahead of Print—Issue.

39. Kirtane AJ, Bangalore S. Why fibrinolytic therapy for STEMI in the COVID-19. Pandemic is not your new best friend. *Circ Cardiovasc Qual Outcomes.* 2020; 13:e006885.

40. Tam CF, Cheung KS, Lam S, et al. Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong, China. *Circ Cardiovasc Qual Outcomes.* 2020; 13 Circoutcomes120006631.

41. Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. *J Med Virol.* 2020; 92:568–576.

42. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. *medRxiv.* 2020; https://doi.org/10.1101/2020.02.06.2002097418.